Zhang Yan, Wang Yang, Anderson Kirsten, Novikov Andrey, Liu Zikou, Pacheco Karin, Dai Shaodong
Department of Biomedical Research, National Jewish Health, Denver, CO 80206, USA; Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO 80045, USA.
Department of Medicine, National Jewish Health, Denver, CO 80206, USA.
Toxicol Appl Pharmacol. 2017 Sep 15;331:69-75. doi: 10.1016/j.taap.2017.05.020. Epub 2017 May 26.
T cell mediated hypersensitivity to nickel (Ni) is one of the most common causes of allergic contact dermatitis. Ni sensitization may also contribute to the failure of Ni containing joint implants, and revision to non-Ni containing hardware can be costly and debilitating. Previously, we identified Ni mimotope peptides, which are reactive to a CD4 T cell clone, ANi2.3 (Vα1, Vβ17), isolated from a Ni hypersensitive patient with contact dermatitis. This T cell is restricted to the major histocompatibility complex class II (MHCII) molecule, Human Leukocyte Antigen (HLA)-DR52c (DRA, DRB3*0301). However, it is not known if Ni induced T cell responses in sensitized joint replacement failure patients are similar to subjects with Ni induced contact dermatitis. Here, we generated DR52c/Ni mimotope tetramers, and used them to test if the same Ni T cell activation mechanism could be generalized to Ni sensitized patients with associated joint implant failure. We confirmed the specificity of these tetramers by staining of ANi2.3T cell transfectomas. The DR52c/Ni mimotope tetramer detected Ni reactive CD4 T cells in the peripheral blood mononuclear cells (PBMC) of patients identified as Ni sensitized by patch testing and a positive Ni LPT. When HLA-typed by a DR52 specific antibody, three out of four patients were DR52 positive. In one patient, Ni stimulation induced the expansion of Vβ17 positive CD4 T cells from 0.8% to 13.3%. We found that the percentage of DR52 positivity and Vβ17 usage in Ni sensitized joint failure patients are similar to Ni sensitized skin allergy patients. Ni independent mimotope tetramers may be a useful tool to identify the Ni reactive CD4 T cells.
T细胞介导的对镍(Ni)的超敏反应是过敏性接触性皮炎最常见的病因之一。镍致敏也可能导致含镍关节植入物失效,而更换为不含镍的硬件成本高昂且会使人虚弱。此前,我们鉴定出了镍模拟表位肽,它们对从一名患有接触性皮炎的镍过敏患者中分离出的CD4 T细胞克隆ANi2.3(Vα1,Vβ17)有反应。该T细胞受限于主要组织相容性复合体II类(MHCII)分子,即人类白细胞抗原(HLA)-DR52c(DRA,DRB3*0301)。然而,尚不清楚镍诱导的致敏关节置换失败患者的T细胞反应是否与镍诱导的接触性皮炎患者相似。在此,我们制备了DR52c/镍模拟表位四聚体,并使用它们来测试相同的镍T细胞激活机制是否可以推广到与关节植入物失败相关的镍致敏患者。我们通过对ANi2.3 T细胞转染瘤进行染色来确认这些四聚体的特异性。DR52c/镍模拟表位四聚体在通过斑贴试验和阳性镍淋巴细胞转化试验鉴定为镍致敏的患者的外周血单个核细胞(PBMC)中检测到了对镍有反应的CD4 T细胞。当用DR52特异性抗体进行HLA分型时,四名患者中有三名DR52呈阳性。在一名患者中,镍刺激使Vβ17阳性CD4 T细胞的比例从0.8%增加到了13.3%。我们发现,镍致敏的关节失败患者中DR52阳性率和Vβ17的使用情况与镍致敏的皮肤过敏患者相似。非镍模拟表位四聚体可能是鉴定对镍有反应的CD4 T细胞的有用工具。